S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.07%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.07%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.07%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.07%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
Log in

NASDAQ:MGENMiragen Therapeutics Stock Price, Forecast & News

$1.16
-0.03 (-2.52 %)
(As of 08/12/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.11
Now: $1.16
$1.20
50-Day Range
$0.87
MA: $1.08
$1.42
52-Week Range
$0.31
Now: $1.16
$2.27
Volume1.17 million shs
Average Volume2.57 million shs
Market Capitalization$65.67 million
P/E RatioN/A
Dividend YieldN/A
Beta2.31
Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous, ocular, and idiopathic pulmonary fibrosis; and MRG-110, an inhibitor of miR-92, a microRNA expressed in endothelial cells for the treatment of heart failure, as well as surgical incisions in high risk populations, severe lacerations, and severe burns in the United States and Japan. The company has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Servier for the development of MRG-110. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.
Read More
Miragen Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.35 out of 5 stars


Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MGEN
CUSIPN/A
Phone720-643-5200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.46 million
Book Value$0.45 per share

Profitability

Net Income$-41,870,000.00
Net Margins-1,393.50%

Miscellaneous

Employees77
Market Cap$65.67 million
Next Earnings Date11/5/2020 (Estimated)
OptionableNot Optionable
$1.16
-0.03 (-2.52 %)
(As of 08/12/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for MGEN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Miragen Therapeutics (NASDAQ:MGEN) Frequently Asked Questions

How has Miragen Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Miragen Therapeutics' stock was trading at $0.6119 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MGEN stock has increased by 89.6% and is now trading at $1.16.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Miragen Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Miragen Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Miragen Therapeutics
.

When is Miragen Therapeutics' next earnings date?

Miragen Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Miragen Therapeutics
.

How were Miragen Therapeutics' earnings last quarter?

Miragen Therapeutics Inc (NASDAQ:MGEN) released its quarterly earnings data on Wednesday, August, 5th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.05. Miragen Therapeutics had a negative net margin of 1,393.50% and a negative return on equity of 164.54%.
View Miragen Therapeutics' earnings history
.

What price target have analysts set for MGEN?

5 brokerages have issued 12-month price objectives for Miragen Therapeutics' stock. Their forecasts range from $3.00 to $6.00. On average, they expect Miragen Therapeutics' share price to reach $5.00 in the next twelve months. This suggests a possible upside of 331.0% from the stock's current price.
View analysts' price targets for Miragen Therapeutics
.

Has Miragen Therapeutics been receiving favorable news coverage?

News headlines about MGEN stock have trended negative on Wednesday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Miragen Therapeutics earned a news sentiment score of -2.2 on InfoTrie's scale. They also assigned media headlines about the medical research company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near term.
View the latest news about Miragen Therapeutics
.

Are investors shorting Miragen Therapeutics?

Miragen Therapeutics saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 206,300 shares, a decrease of 29.5% from the March 15th total of 292,600 shares. Based on an average trading volume of 2,830,000 shares, the days-to-cover ratio is currently 0.1 days.
View Miragen Therapeutics' Short Interest
.

Who are some of Miragen Therapeutics' key competitors?

What other stocks do shareholders of Miragen Therapeutics own?

Who are Miragen Therapeutics' key executives?

Miragen Therapeutics' management team includes the following people:
  • Dr. William Stuart Marshall Ph.D., Co-Founder, Pres, CEO & Director (Age 55)
  • Mr. Adam Scott Levy, Chief Bus. Officer (Age 41)
  • Dr. Paul D. Rubin, Exec. VP of R&D (Age 65)
  • Eric N. Olson, Co-Founder & Chairman of Scientific Advisory Board
  • Dr. Michael R. Bristow, Co-Founder & Member of the Scientific Advisory Board (Age 74)

What is Miragen Therapeutics' stock symbol?

Miragen Therapeutics trades on the NASDAQ under the ticker symbol "MGEN."

Who are Miragen Therapeutics' major shareholders?

Miragen Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Game Plan Financial Advisors LLC (0.13%).
View institutional ownership trends for Miragen Therapeutics
.

Which institutional investors are buying Miragen Therapeutics stock?

MGEN stock was bought by a variety of institutional investors in the last quarter, including Game Plan Financial Advisors LLC.
View insider buying and selling activity for Miragen Therapeutics
.

How do I buy shares of Miragen Therapeutics?

Shares of MGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Miragen Therapeutics' stock price today?

One share of MGEN stock can currently be purchased for approximately $1.16.

How big of a company is Miragen Therapeutics?

Miragen Therapeutics has a market capitalization of $65.67 million and generates $4.46 million in revenue each year. The medical research company earns $-41,870,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis. Miragen Therapeutics employs 77 workers across the globe.

What is Miragen Therapeutics' official website?

The official website for Miragen Therapeutics is www.signalgenetics.com.

How can I contact Miragen Therapeutics?

Miragen Therapeutics' mailing address is 6200 LOOKOUT ROAD, BOULDER CO, 80301. The medical research company can be reached via phone at 720-643-5200 or via email at [email protected]

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.